BTAI Logo

BioXcel Therapeutics, Inc. (BTAI) 

NASDAQ
Market Cap
$17.42M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
582 of 958
Rank in Industry
317 of 549

Largest Insider Buys in Sector

BTAI Stock Price History Chart

BTAI Stock Performance

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the …

Insider Activity of BioXcel Therapeutics, Inc.

Over the last 12 months, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $457,050 worth of BioXcel Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at BioXcel Therapeutics, Inc. have bought $0 and sold $34.4M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,108 shares for transaction amount of $14,514 was made by MUELLER PETER (director) on 2019‑08‑23.

List of Insider Buy and Sell Transactions, BioXcel Therapeutics, Inc.

2024-12-16SaleCEO and President
3,117
0.0062%
$0.36$1,131-14.76%
2024-12-16SaleChief Scientific Officer
430
0.0008%
$0.35$152-14.76%
2024-12-16SaleChief Financial Officer
577
0.0011%
$0.36$207-14.76%
2024-12-16SaleSee Remarks
165
0.0003%
$0.35$58-14.76%
2024-10-03SaleChief Scientific Officer
7,175
0.0181%
$0.55$3,946-1.40%
2024-10-03SaleSee Remarks
6,863
0.0173%
$0.55$3,775-1.40%
2024-10-03SaleChief Financial Officer
7,175
0.0181%
$0.55$3,946-1.40%
2024-10-03SaleSee Remarks
5,556
0.014%
$0.55$3,056-1.40%
2024-10-03SaleChief Commercial Officer
6,272
0.0158%
$0.55$3,450-1.40%
2024-09-16SaleCEO and President
1,982
0.0052%
$0.69$1,367-13.25%
2024-09-16SaleChief Scientific Officer
355
0.0009%
$0.69$245-13.25%
2024-09-16SaleSee Remarks
345
0.0009%
$0.69$238-13.25%
2024-09-16SaleChief Financial Officer
356
0.0009%
$0.69$246-13.25%
2024-09-16SaleChief Commercial Officer
215
0.0006%
$0.69$149-13.25%
2024-09-16SaleSee Remarks
138
0.0004%
$0.69$95-13.25%
2024-06-17SaleCEO and President
2,134
0.0051%
$1.28$2,739-53.95%
2024-06-17SaleChief Scientific Officer
372
0.0009%
$1.28$476-53.95%
2024-06-17SaleSee Remarks
361
0.0008%
$1.26$456-53.95%
2024-06-17SaleChief Financial Officer
372
0.0009%
$1.26$470-53.95%
2024-06-17SaleSee Remarks
155
0.0004%
$1.28$199-53.95%

Insider Historical Profitability

94.37%
Mehta VimalCEO and President
59605
0.1201%
$0.35912+91.12%
Yocca FrankChief Scientific Officer
28931
0.0583%
$0.35510+91.88%
Steinhart Richard IChief Financial Officer
20932
0.0422%
$0.3538+87.62%
MUELLER PETERdirector
168320
0.3392%
$0.3560+104.84%
Nandabalan Krishnan
0
0%
$0.3515+93.45%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$7.03M6.652.49M-0.97%-$68,943.36<0.0001
BlackRock$3.75M3.541.33M-3.36%-$130,137.36<0.0001
The Vanguard Group$3.1M2.931.1M+0.91%+$27,951.83<0.0001
Ameriprise Financial$1.63M1.54579,164+7.04%+$107,442.03<0.0001
State Street$1.31M1.24464,908+5.58%+$69,304.34<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.